Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levacetylleucine - IntraBio

Next Previous
Drug Profile

Levacetylleucine - IntraBio

Alternative Names: AQNEURSA; IB-1001 - IntraBio; N-Acetyl-L-Leucine - IntraBio

Latest Information Update: 05 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Munich; University of Oxford
  • Developer IntraBio
  • Class Acetamides; Amino acids; Esters; Neuroprotectants; Pentanoic acids; Small molecules; Vestibular disorder therapies
  • Mechanism of Action Calcium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tay-Sachs disease; Niemann-Pick disease type C; Ataxia telangiectasia
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Niemann-Pick disease type C
  • Phase III Ataxia telangiectasia
  • Phase II Sandhoff disease; Tay-Sachs disease

Most Recent Events

  • 29 Jul 2025 Preregistration for Niemann-Pick disease type C (In adolescents, In children, In the elderly, In adults) in European Union (PO) before July 2025
  • 29 Jul 2025 European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends approval of Levacetylleucine for Niemann-Pick disease type C in European Union
  • 29 Jul 2025 IntraBio announces intention to submit global regulatory submissions for levacetylleucine for Niemann-Pick disease type C in 2025 (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top